Zydus Lifesciences arm, MSN Labs collaborate to license, supply cancer drug Cabozantinib in US

Ahmedabad: Zydus Lifesciences Ltd., a global innovation driven healthcare company has announced that its wholly owned subsidiary, Zydus Lifesciences Global FZE has entered into an exclusive licensing and supply agreement with MSN Laboratories for Cabozantinib Tablets (a generic version of CABOMETYX) for the US market.

As per the terms of the agreement, MSN Laboratories will be in charge of manufacturing and supplying the generic version of CABOMETYX, following the receipt of regulatory approval. Zydus will exclusively market, distribute, and sell the Product in the US market. MSN was a first sole ANDA applicant for Cabozantinib Tablets, to submit a substantially complete ANDA with a paragraph IV certification and therefore may be eligible for 180 days of generic drug exclusivity for the generic version of CABOMETYX.

Speaking on the development, Managing Director of Zydus Lifesciences Ltd., Dr. Sharvil Patel said, “This partnership with MSN Laboratories underscores our commitment to provide patients with access to high-quality, affordable medications. Cabozantinib Tablets is an important treatment option for many cancer patients, and we are pleased to work with MSN to bring the generic version of CABOMETYX to the US market.”

Dr. MSN Reddy, Founder, Chairman & Managing Director - MSN Group said, "As a leading global developer and manufacturer of vertically integrated generics, we are pleased to partner with Zydus on this significant First to Market opportunity. Bringing Cabozantinib Tablets to market represents another example of MSN's global development, manufacturing, and regulatory expertise. We are confident that working with Zydus will allow us to successfully commercialize Cabozantinib while advancing our mission of enabling access to high quality, affordable medicines.

The total addressable market opportunity of Cabozantinib Tablets in US is approximately US$ 1,464 million (IQVIA MAT Mar 2024).